Back to the list
Congress: ECR25
Poster Number: C-25665
Type: Poster: EPOS Radiologist (scientific)
Authorblock: M. Thormann1, H-J. Meyer2, A. Wienke3, J. Borggrefe4, A. Surov4; 1Magdeburg/DE, 2Leipzig/DE, 3Halle/DE, 4Minden/DE
Disclosures:
Maximilian Thormann: Nothing to disclose
Hans-Jonas Meyer: Nothing to disclose
Andreas Wienke: Nothing to disclose
Jan Borggrefe: Nothing to disclose
Alexey Surov: Nothing to disclose
Keywords: Oncology, CT, Computer Applications-General, Cancer
Purpose Sarcopenia, a progressive and generalized skeletal muscle disorder, poses a major clinical concern in oncology. It can lead to reduced treatment tolerance, higher toxicity, longer hospital stays, and poorer survival. Although the overall prevalence of sarcopenia in solid tumors is often reported at around one-third of patients, substantial variability exists across regions. This variability may stem from demographic factors (e.g., age and body habitus), lifestyle (diet, physical activity), and different healthcare practices. Additionally, heterogeneous cutoff thresholds for “low skeletal muscle...
Read more Methods and materials Literature Search We searched MEDLINE, Embase, and SCOPUS up to December 2022. We used the string “(low skeletal muscle mass OR sarcopenia) AND (cancer)” and supplemented it with tumor-specific searches (e.g., breast cancer, esophageal cancer, pancreatic cancer, etc.). Titles and abstracts underwent screening, followed by full-text evaluation. Inclusion and Exclusion Criteria Studies were included if they: Enrolled adult patients with malignant solid tumors. Assessed LSMM or sarcopenia via CT at L3 level, with muscle area normalized by height (SMI). Reported prevalence of LSMM or sarcopenia. Provided data...
Read more Results Search Results and Study Characteristics After removing duplicates, 2,567 abstracts were screened. Ultimately, 280 studies with 81,885 patients (roughly 58% men, 42% women) were included. Mean patient age was around 62 years, slightly higher in European cohorts. Most studies (69%) were retrospective.By region, 107 studies originated in Europe (16,061 patients), 42 in North America (19,257 patients), and 131 in Asia (45,567 patients). The largest sample sizes concerned colorectal (44 studies, 32,823 patients) and gastric cancers (35 studies, 9,950 patients). Some entities,...
Read more Conclusion This meta-analysis is the first to compare CT-defined sarcopenia in cancer patients across multiple regions (Europe, North America, Asia), encompassing 280 studies and over 80,000 individuals. Our findings confirm that while sarcopenia occurs in roughly one-third of all cancer patients overall, regional prevalence varies substantially.Regional DisparitiesEurope consistently showed higher overall prevalence (45.6%) than Asia (29.6%) or North America (41.2%). Possible explanations include demographic differences (older average age and higher prevalence of comorbidities in certain European cohorts), lifestyle factors (lower physical...
Read more References [1]      Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31. https://doi.org/10.1093/ageing/afy169.[2]      Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–95. https://doi.org/10.1016/S1470-2045(10)70218-7.[3]      Sun G, Li Y, Peng Y, Lu D, Zhang F, Cui X, et al. Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal...
Read more
GALLERY